Background <p>Chimeric antigen receptor macrophage (CAR-M) therapy has promising therapeutic potential in solid tumors, yet challenges remain in target compatibility and systemic toxicity.</p> Methods <p>In this study, we screened the CD47-scFv sequence of CAR-M as the extracellular structure. We then constructed a classical CD47 CAR-M incorporated the costimulatory domain of the α1β1 integrin-mediated Fc-gamma receptor I (FcRI) signaling component. Subsequently,…
Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy
Journal for ImmunoTherapy of Cancer | | Du, F., Jiang, M., Qiu, J., He, A., Liu, M., Xu, Y., Gong, X., Wang, X., Zhang, H., Zhang, X., Xu, X., Lu, L., Wang, Z., Ning, P.
Topics: blood-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer